Rare Revolution Magazine focuses on newborn screening (NBS) in recent issue co-sponsored by Travere Therapeutics
Newborn screening (NBS) is one of the most successful disease prevention programs in the United States, identifying 13,000 babies every year with treatable diseases. Travere is supporting transformative work that can potentially modernize NBS and shorten the diagnostic odyssey for countless people.
To help bring attention to the importance of modernizing newborn screening (NBS), the challenges faced by NBS systems worldwide, and the work of advocates and others to improve NBS for rare families, we co-sponsored the recent NBS-focused issue of Rare Revolution Magazine, now available online.